Colposcopy Referral and CIN3+Risk of Human Papillomavirus Genotyping Strategies in Cervical Cancer Screening

被引:2
作者
Kroon, Kelsi R. [1 ,2 ]
Bogaards, Johannes A. [1 ,2 ]
Heideman, Danielle A. M. [3 ,4 ,5 ]
Meijer, Chris J. L. M. [3 ,4 ]
Berkhof, Johannes [1 ,2 ]
机构
[1] Vrije Univ Amsterdam, Epidemiol & Data Sci, Amsterdam UMC, De Boelelaan 1089a, NL-1081 HV Amsterdam, Netherlands
[2] Amsterdam Publ Hlth Res Inst, Methodol, Amsterdam, Netherlands
[3] Vrije Univ Amsterdam, Pathol, Amsterdam UMC, Amsterdam, Netherlands
[4] Canc Ctr Amsterdam, Imaging & Biomarkers, Amsterdam, Netherlands
[5] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Groningen, Netherlands
基金
欧盟地平线“2020”;
关键词
RISK HUMAN-PAPILLOMAVIRUS; INTRAEPITHELIAL NEOPLASIA; BASE-LINE; CYTOLOGY; WOMEN; IMPLEMENTATION; GUIDELINES; POBASCAM;
D O I
10.1158/1055-9965.EPI-24-0046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: High-risk human papillomavirus (hrHPV)-based cervical cancer screening in the Netherlands led to a substantial increase in number of colposcopy referrals and low-grade lesions detected. Genotyping strategies may be employed to lower the screening-related burden.Methods: We evaluated 14 triage strategies with genotyping (HPV16/18 or HPV16/18/31/33/45/52/58) for hrHPV-positive borderlineormilddyskaryosis (BMD)ornormal cytology,usingdata from a population-based hrHPV-based screening trial with 5-year interval (POBASCAM). We considered colposcopy referral at baseline, after 6-month repeat cytology and after 5-year hrHPV testing. Performance was evaluated by one-round positive and negative predictive value (PPVandNPV) for CIN3+ and by two-roundcolposcopy referral rate. To identify efficient strategies, they were ordered by the one-round colposcopy referral rate. Adjacent strategies were compared by the marginal PPV for detecting one additional CIN3+ (mPPV).Results: The most conservative strategy (repeat cytology after BMD and HPV16/18/31/33/45/52/58-positive normal cytology, next round otherwise) yielded an mPPV of 28%, NPV of 98.2%, and two-round colposcopy referral rate of 47.2%. Adding direct referral after BMD or genotype-positive BMD yielded an mPPV <= 8.2%, NPV >= 98.5% and an increase in colposcopy referral rate of 1.9% to 6.5%. Adding direct referral after HPV16/18-positive normal cytology yielded an mPPV <= 3.5%, NPV >= 99.5% and an increase in colposcopy referral rate of 13.9%.Conclusions: Direct colposcopy referral of women with BMD or normal cytology is unlikely to be efficient, but genotype-guided direct referral after BMD may be considered because the increase in colposcopies is limited.Impact: hrHPV screening programs can become very efficient when immediate colposcopy referral is limited to women at highest CIN3+ risk. See related In the Spotlight, p. 979Impact: hrHPV screening programs can become very efficient when immediate colposcopy referral is limited to women at highest CIN3+ risk. See related In the Spotlight, p. 979
引用
收藏
页码:1037 / 1045
页数:9
相关论文
共 50 条
  • [41] Prevalence and Genotyping of High Risk Human Papillomavirus in Cervical Cancer Samples from Punjab, Pakistan
    Siddiqa, Abida
    Zainab, Maidah
    Qadri, Ishtiaq
    Bhatti, Muhammad Faraz
    Parish, Joanna L.
    VIRUSES-BASEL, 2014, 6 (07): : 2762 - 2777
  • [42] Establishment and Application of a Method for High-Risk Human Papillomavirus Genotyping in Cervical Cancer Tissue
    Zou, Ruanmin
    Xie, Wangkai
    Wang, Huijing
    Wang, Jian
    Xiao, Lanlan
    Ji, Shuhui
    Chen, Xiangmin
    Zhang, Lifang
    Xue, Xiangyang
    Chen, Jun
    CLINICAL LABORATORY, 2016, 62 (06) : 1075 - 1085
  • [43] Reliability of the Xpert HPV Assay to Detect High-Risk Human Papillomavirus DNA in a Colposcopy Referral Population
    Castle, Philip E.
    Smith, Katherine M.
    Davis, Thomas E.
    Schmeler, Kathleen M.
    Ferris, Daron G.
    Savage, Ashlyn H.
    Gray, Jermaine E.
    Stoler, Mark H.
    Wright, Thomas C., Jr.
    Ferenczy, Alex
    Einstein, Mark H.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2015, 143 (01) : 126 - 133
  • [44] High-risk human papillomavirus genotyping in cervical cancers in Tanzania
    Murenzi, Gad
    Vuhahula, Edda
    Kimambo, Asteria
    Matiku, Subira
    Tuyishime, Obed
    Liwa, Edwin
    Habanabakize, Thomas
    Rugengamanzi, Eulade
    Malango, Atuganile
    Kubwimana, Gallican
    Anastos, Kathryn
    Castle, Philip E.
    INFECTIOUS AGENTS AND CANCER, 2024, 19 (01):
  • [45] Comparing cytology, colposcopy and human papillomavirus cervical intraepithelial lesion screening methods in women with systemic lupus erythematosus
    Garcia-Carrasco, Mario
    Mendoza-Pinto, Claudia
    Mendez-Martinez, Socorro
    Rodriguez-Reyes, Ariadna
    Munguia-Realpozo, Pamela
    Taboada-Cole, Alejandro
    Vallejo-Ruiz, Veronica
    Etchegaray-Morales, Net
    Jimenez-Herrera, Rebeca
    Juarez-Melchor, Daniela
    Villanueva-Lopez, Isai
    LUPUS, 2020, 29 (09) : 1060 - 1066
  • [46] Current cervical cancer prevention strategies including cervical screening and prophylactic human papillomavirus vaccination: a review
    Elfstrom, Klara Miriam
    Herweijer, Eva
    Sundstrom, Karin
    Arnheim-Dahlstrom, Lisen
    CURRENT OPINION IN ONCOLOGY, 2014, 26 (01) : 120 - 129
  • [47] Human papillomavirus detection using PCR and ATR-FTIR for cervical cancer screening
    Rymsza, Taciana
    Ribeiro, Eliane Aline
    das Chagas e Silva de Carvalho, Luis Felipe
    Bhattacharjee, Tanmoy
    Canevari, Renata de Azevedo
    SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY, 2018, 196 : 238 - 246
  • [48] Human papillomavirus testing versus cytology in primary cervical cancer screening: End-of-study and extended follow-up results from the Canadian cervical cancer screening trial
    Isidean, Sandra D.
    Mayrand, Marie-Helene
    Ramanakumar, Agnihotram V.
    Gilbert, Laura
    Reid, Stephanie L.
    Rodrigues, Isabel
    Ferenczy, Alex
    Ratnam, Sam
    Coutlee, Francois
    Franco, Eduardo L.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (11) : 2456 - 2466
  • [49] Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus
    Kim, Jane J.
    Burger, Emily A.
    Sy, Stephen
    Campos, Nicole G.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2017, 109 (02):
  • [50] Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening in the United States Is It Time?
    Flanagan, Melina B.
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2018, 142 (06) : 688 - 692